Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lihe Hongxin is a Shenzhen-based venture investment partnership and private fund focused on early-stage investments across multiple emerging industries. Its investment scope includes biomedicine and healthcare alongside new energy, new materials, electronic information, integrated circuits, and high-end equipment. Available public information indicates that the firm operates as an investment vehicle rather than as a drug developer, healthcare operator, or therapeutic platform company. For biotech analysts, the relevant takeaway is that Lihe Hongxin appears to be a cross-sector Chinese venture investor with participation in life science deals, not a life science company itself.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lihe Hongxin.